Sunbird Bio
Sangeeta Bhatia is a highly accomplished professional with a diverse background in academia and entrepreneurship. Currently serving as a Professor and Director at the Marble Center for Cancer Nanomedicine at Massachusetts Institute of Technology, Sangeeta is also involved in several start-up ventures including Matrisome Bio, Port Therapeutics, Satellite Bio, and Glympse Bio. With a strong academic foundation from Harvard Medical School, Massachusetts Institute of Technology, and Brown University, Sangeeta has made significant contributions in the fields of bioengineering and medicine. Additionally, Sangeeta has held key roles at organizations such as Vertex Pharmaceuticals, Hepregen, and the National Cancer Institute, showcasing their expertise and leadership in the scientific community.
Sunbird Bio
1 followers
Sunbird Bio is a leader in protein-based diagnostic tests, becoming the first company to overcome the challenge of accurately detecting and differentiating the specific proteins that aggregate, and therefore signal the presence of Alzheimer’s disease, with a simple blood draw. We are addressing the tremendous, growing need for more reliable and sensitive diagnostic tests to accelerate drug development and enhance patient care. Our pipeline of innovative, non-invasive technologies, such as our APEX technology, will empower researchers and clinicians with unparalleled insights not available from current tests.